Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EndoTAG-1 + Gemcitabine in Pancreatic Cancer
NCT03126435Phase 3Completed
- Sponsor
- SynCore Biotechnology
- Start
- Oct 2018
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of EndoTAG-1 in pancreatic adenocarcinoma (PDAC), sponsored by SynCore Biotechnology. Started Oct 2018; status: completed.
02
Drugs
EndoTAG-1
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03126435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03126435.